Market Size of Human Insulin Drugs Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 27.96 Billion |
| Market Size (2029) | USD 33.81 Billion |
| CAGR (2024 - 2029) | 3.87 % |
| Fastest Growing Market | North America |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Insulin Market Analysis
The Human Insulin Drugs Market size is estimated at USD 27.96 billion in 2024, and is expected to reach USD 33.81 billion by 2029, growing at a CAGR of 3.87% during the forecast period (2024-2029).
The COVID-19 pandemic has had a substantial impact on the Human Insulin Drugs Market. Type-1 diabetes patients are impacted more during Covid-19. People with diabetes are having a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes will have more chances to get into serious complications rather than normal people.
Diabetes is associated with many health complications. People with diabetes have a 300% increased risk of being hospitalized compared to those without diabetes, and thus, they incur more healthcare expenses compared to non-diabetic people. Patients with Type 2 diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates. Furthermore, patients attempting to control their blood glucose levels, so as to prevent the long-term complications associated with fluctuations in blood glucose levels, are at greater risk for overcorrection and the resultant hypoglycemia.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Insulin Industry Segmentation
The hormone class of drugs includes human insulin. In place of the insulin that the body ordinarily produces, human insulin is used. It functions by assisting in the movement of blood sugar into different bodily tissues, where it is used as an energy source. It also prevents the liver from generating additional sugar. The human insulin drug market is set to register a CAGR of more than 3% during the forecast period. The human insulin drug market is segmented by product type (traditional human insulins, basal or long-acting insulins, bolus or fast-acting insulins, insulin combinations, and biosimilar insulins), Type ( Hospital/Clinics, Home/Personal) and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America). The report offers the value (in USD) and volume (in units) for the above segments.
| Product Type | |||||||
| |||||||
| |||||||
| |||||||
| |||||||
|
| End User | |
| Hospital/Clinics | |
| Home/Personal |
| Geography | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Human Insulin Drugs Market Size Summary
The human insulin market is poised for growth, driven by the increasing prevalence of diabetes and the critical role of insulin in managing this condition. The market is experiencing a steady expansion, with North America, particularly the United States, leading due to its high diabetes rates linked to sedentary lifestyles. The U.S. market is significant for insulin manufacturers, with a substantial portion of revenues generated from this region. The dominance of long-acting insulins like Lantus and Humalog underscores the importance of the U.S. market in the global landscape. The absence of generic competitors in the traditional North American insulin market further solidifies its growth prospects. The market's expansion is also supported by the ongoing development of innovative insulin formulations and delivery methods, such as oral insulin, which promise to enhance patient adherence and treatment outcomes.
The global human insulin market is characterized by a high level of consolidation, with a few major players maintaining a strong presence worldwide. Companies like Novo Nordisk, Eli Lilly, and Sanofi are at the forefront, engaging in strategic alliances and product innovations to strengthen their market positions. Recent developments, such as Eli Lilly's introduction of a biosimilar insulin at a reduced cost and Novo Nordisk's advancements in insulin injection trials, highlight the dynamic nature of the market. The focus on developing more convenient and effective insulin delivery systems, including oral formulations, reflects the industry's commitment to improving diabetes management. As the market continues to evolve, these factors are expected to drive sustained growth and transformation in the human insulin sector.
Human Insulin Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Drivers
-
1.3 Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Product Type
-
2.1.1 Basal or Long-acting Insulins
-
2.1.1.1 Lantus (Insulin glargine)
-
2.1.1.2 Levemir (Insulin detemir)
-
2.1.1.3 Toujeo (Insulin glargine)
-
2.1.1.4 Tresiba (Insulin degludec)
-
2.1.1.5 Basaglar (Insulin glargine)
-
-
2.1.2 Bolus or Fast-acting Insulins
-
2.1.2.1 NovoRapid/Novolog (Insulin aspart)
-
2.1.2.2 Humalog (Insulin lispro)
-
2.1.2.3 Apidra (Insulin glulisine)
-
2.1.2.4 FIASP (Insulin aspart)
-
2.1.2.5 Admelog (Insulin lispro)
-
-
2.1.3 Traditional Human Insulins
-
2.1.3.1 Novolin/Actrapid/Insulatard
-
2.1.3.2 Humulin
-
2.1.3.3 Insuman
-
-
2.1.4 Combination Insulins
-
2.1.4.1 NovoMix (Biphasic Insulin aspart)
-
2.1.4.2 Ryzodeg (Insulin degludec/Insulin aspart)
-
2.1.4.3 Xultophy (Insulin degludec/Liraglutide)
-
2.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)
-
-
2.1.5 Biosimilar Insulins
-
2.1.5.1 Insulin Glargine Biosimilars
-
2.1.5.2 Human Insulin Biosimilars
-
-
-
2.2 End User
-
2.2.1 Hospital/Clinics
-
2.2.2 Home/Personal
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.1.1 Basal or Long-acting Insulins
-
2.3.1.1.2 Bolus or Fast-acting Insulins
-
2.3.1.1.3 Traditional Human Insulins
-
2.3.1.1.4 Combination Insulins
-
2.3.1.1.5 Biosimilar Insulins
-
-
2.3.1.2 Canada
-
2.3.1.2.1 Basal or Long-acting Insulins
-
2.3.1.2.2 Bolus or Fast-acting Insulins
-
2.3.1.2.3 Traditional Human Insulins
-
2.3.1.2.4 Combination Insulins
-
2.3.1.2.5 Biosimilar Insulins
-
-
2.3.1.3 Rest of North America
-
2.3.1.3.1 Basal or Long-acting Insulins
-
2.3.1.3.2 Bolus or Fast-acting Insulins
-
2.3.1.3.3 Traditional Human Insulins
-
2.3.1.3.4 Combination Insulins
-
2.3.1.3.5 Biosimilar Insulins
-
-
-
2.3.2 Europe
-
2.3.2.1 France
-
2.3.2.1.1 Basal or Long-acting Insulins
-
2.3.2.1.2 Bolus or Fast-acting Insulins
-
2.3.2.1.3 Traditional Human Insulins
-
2.3.2.1.4 Combination Insulins
-
2.3.2.1.5 Biosimilar Insulins
-
-
2.3.2.2 Germany
-
2.3.2.2.1 Basal or Long-acting Insulins
-
2.3.2.2.2 Bolus or Fast-acting Insulins
-
2.3.2.2.3 Traditional Human Insulins
-
2.3.2.2.4 Combination Insulins
-
2.3.2.2.5 Biosimilar Insulins
-
-
2.3.2.3 Italy
-
2.3.2.3.1 Basal or Long-acting Insulins
-
2.3.2.3.2 Bolus or Fast-acting Insulins
-
2.3.2.3.3 Traditional Human Insulins
-
2.3.2.3.4 Combination Insulins
-
2.3.2.3.5 Biosimilar Insulins
-
-
2.3.2.4 Spain
-
2.3.2.4.1 Basal or Long-acting Insulins
-
2.3.2.4.2 Bolus or Fast-acting Insulins
-
2.3.2.4.3 Traditional Human Insulins
-
2.3.2.4.4 Combination Insulins
-
2.3.2.4.5 Biosimilar Insulins
-
-
2.3.2.5 United Kingdom
-
2.3.2.5.1 Basal or Long-acting Insulins
-
2.3.2.5.2 Bolus or Fast-acting Insulins
-
2.3.2.5.3 Traditional Human Insulins
-
2.3.2.5.4 Combination Insulins
-
2.3.2.5.5 Biosimilar Insulins
-
-
2.3.2.6 Russia
-
2.3.2.6.1 Basal or Long-acting Insulins
-
2.3.2.6.2 Bolus or Fast-acting Insulins
-
2.3.2.6.3 Traditional Human Insulins
-
2.3.2.6.4 Combination Insulins
-
2.3.2.6.5 Biosimilar Insulins
-
-
2.3.2.7 Rest of Europe
-
2.3.2.7.1 Basal or Long-acting Insulins
-
2.3.2.7.2 Bolus or Fast-acting Insulins
-
2.3.2.7.3 Traditional Human Insulins
-
2.3.2.7.4 Combination Insulins
-
2.3.2.7.5 Biosimilar Insulins
-
-
-
2.3.3 Latin America
-
2.3.3.1 Mexico
-
2.3.3.1.1 Basal or Long-acting Insulins
-
2.3.3.1.2 Bolus or Fast-acting Insulins
-
2.3.3.1.3 Traditional Human Insulins
-
2.3.3.1.4 Combination Insulins
-
2.3.3.1.5 Biosimilar Insulins
-
-
2.3.3.2 Brazil
-
2.3.3.2.1 Basal or Long-acting Insulins
-
2.3.3.2.2 Bolus or Fast-acting Insulins
-
2.3.3.2.3 Traditional Human Insulins
-
2.3.3.2.4 Combination Insulins
-
2.3.3.2.5 Biosimilar Insulins
-
-
2.3.3.3 Rest of Latin America
-
2.3.3.3.1 Basal or Long-acting Insulins
-
2.3.3.3.2 Bolus or Fast-acting Insulins
-
2.3.3.3.3 Traditional Human Insulins
-
2.3.3.3.4 Combination Insulins
-
2.3.3.3.5 Biosimilar Insulins
-
-
-
2.3.4 Asia-Pacific
-
2.3.4.1 Japan
-
2.3.4.1.1 Basal or Long-acting Insulins
-
2.3.4.1.2 Bolus or Fast-acting Insulins
-
2.3.4.1.3 Traditional Human Insulins
-
2.3.4.1.4 Combination Insulins
-
2.3.4.1.5 Biosimilar Insulins
-
-
2.3.4.2 South Korea
-
2.3.4.2.1 Basal or Long-acting Insulins
-
2.3.4.2.2 Bolus or Fast-acting Insulins
-
2.3.4.2.3 Traditional Human Insulins
-
2.3.4.2.4 Combination Insulins
-
2.3.4.2.5 Biosimilar Insulins
-
-
2.3.4.3 China
-
2.3.4.3.1 Basal or Long-acting Insulins
-
2.3.4.3.2 Bolus or Fast-acting Insulins
-
2.3.4.3.3 Traditional Human Insulins
-
2.3.4.3.4 Combination Insulins
-
2.3.4.3.5 Biosimilar Insulins
-
-
2.3.4.4 India
-
2.3.4.4.1 Basal or Long-acting Insulins
-
2.3.4.4.2 Bolus or Fast-acting Insulins
-
2.3.4.4.3 Traditional Human Insulins
-
2.3.4.4.4 Combination Insulins
-
2.3.4.4.5 Biosimilar Insulins
-
-
2.3.4.5 Australia
-
2.3.4.5.1 Basal or Long-acting Insulins
-
2.3.4.5.2 Bolus or Fast-acting Insulins
-
2.3.4.5.3 Traditional Human Insulins
-
2.3.4.5.4 Combination Insulins
-
2.3.4.5.5 Biosimilar Insulins
-
-
2.3.4.6 Vietnam
-
2.3.4.6.1 Basal or Long-acting Insulins
-
2.3.4.6.2 Bolus or Fast-acting Insulins
-
2.3.4.6.3 Traditional Human Insulins
-
2.3.4.6.4 Combination Insulins
-
2.3.4.6.5 Biosimilar Insulins
-
-
2.3.4.7 Malaysia
-
2.3.4.7.1 Basal or Long-acting Insulins
-
2.3.4.7.2 Bolus or Fast-acting Insulins
-
2.3.4.7.3 Traditional Human Insulins
-
2.3.4.7.4 Combination Insulins
-
2.3.4.7.5 Biosimilar Insulins
-
-
2.3.4.8 Indonesia
-
2.3.4.8.1 Basal or Long-acting Insulins
-
2.3.4.8.2 Bolus or Fast-acting Insulins
-
2.3.4.8.3 Traditional Human Insulins
-
2.3.4.8.4 Combination Insulins
-
2.3.4.8.5 Biosimilar Insulins
-
-
2.3.4.9 Philippines
-
2.3.4.9.1 Basal or Long-acting Insulins
-
2.3.4.9.2 Bolus or Fast-acting Insulins
-
2.3.4.9.3 Traditional Human Insulins
-
2.3.4.9.4 Combination Insulins
-
2.3.4.9.5 Biosimilar Insulins
-
-
2.3.4.10 Thailand
-
2.3.4.10.1 Basal or Long-acting Insulins
-
2.3.4.10.2 Bolus or Fast-acting Insulins
-
2.3.4.10.3 Traditional Human Insulins
-
2.3.4.10.4 Combination Insulins
-
2.3.4.10.5 Biosimilar Insulins
-
-
2.3.4.11 Rest of Asia-Pacific
-
2.3.4.11.1 Basal or Long-acting Insulins
-
2.3.4.11.2 Bolus or Fast-acting Insulins
-
2.3.4.11.3 Traditional Human Insulins
-
2.3.4.11.4 Combination Insulins
-
2.3.4.11.5 Biosimilar Insulins
-
-
-
2.3.5 Middle-East and Africa
-
2.3.5.1 Saudi Arabia
-
2.3.5.1.1 Basal or Long-acting Insulins
-
2.3.5.1.2 Bolus or Fast-acting Insulins
-
2.3.5.1.3 Traditional Human Insulins
-
2.3.5.1.4 Combination Insulins
-
2.3.5.1.5 Biosimilar Insulins
-
-
2.3.5.2 Iran
-
2.3.5.2.1 Basal or Long-acting Insulins
-
2.3.5.2.2 Bolus or Fast-acting Insulins
-
2.3.5.2.3 Traditional Human Insulins
-
2.3.5.2.4 Combination Insulins
-
2.3.5.2.5 Biosimilar Insulins
-
-
2.3.5.3 Egypt
-
2.3.5.3.1 Basal or Long-acting Insulins
-
2.3.5.3.2 Bolus or Fast-acting Insulins
-
2.3.5.3.3 Traditional Human Insulins
-
2.3.5.3.4 Combination Insulins
-
2.3.5.3.5 Biosimilar Insulins
-
-
2.3.5.4 Oman
-
2.3.5.4.1 Basal or Long-acting Insulins
-
2.3.5.4.2 Bolus or Fast-acting Insulins
-
2.3.5.4.3 Traditional Human Insulins
-
2.3.5.4.4 Combination Insulins
-
2.3.5.4.5 Biosimilar Insulins
-
-
2.3.5.5 South Africa
-
2.3.5.5.1 Basal or Long-acting Insulins
-
2.3.5.5.2 Bolus or Fast-acting Insulins
-
2.3.5.5.3 Traditional Human Insulins
-
2.3.5.5.4 Combination Insulins
-
2.3.5.5.5 Biosimilar Insulins
-
-
2.3.5.6 Rest of Middle-East and Africa
-
2.3.5.6.1 Basal or Long-acting Insulins
-
2.3.5.6.2 Bolus or Fast-acting Insulins
-
2.3.5.6.3 Traditional Human Insulins
-
2.3.5.6.4 Combination Insulins
-
2.3.5.6.5 Biosimilar Insulins
-
-
-
-
Human Insulin Drugs Market Size FAQs
How big is the Human Insulin Drugs Market?
The Human Insulin Drugs Market size is expected to reach USD 27.96 billion in 2024 and grow at a CAGR of 3.87% to reach USD 33.81 billion by 2029.
What is the current Human Insulin Drugs Market size?
In 2024, the Human Insulin Drugs Market size is expected to reach USD 27.96 billion.
